How often to get bloodwork on TRT

Two things happen before anyone talks about frequency: a diagnosis of hypogonadism and a baseline panel. That baseline is the reference every later draw is compared against, and it is where the hematocrit, PSA, and lipid values that get tracked over time are first recorded.

After therapy starts, the guidelines converge on a similar shape. The Endocrine Society advises evaluating the patient 3 to 6 months after starting testosterone and then annually. The AUA guideline says an initial follow-up testosterone level should be measured after an appropriate interval, and that testosterone levels should be measured every 6 to 12 months on therapy. So the pattern is baseline, an early recheck around the 3 to 6 month mark, then a periodic rhythm. The exact dates are a clinical decision, not a number this page can set for you.

The point of measuring testosterone on therapy is to see whether the dose is landing the level where the guideline aims it - the Endocrine Society describes targeting the mid-normal range. The catch is that a single number only means something if you know when it was drawn, because testosterone rises and falls differently by formulation.

For a gel, the AndroGel label uses a pre-dose morning sample taken around 14 and 28 days after starting or adjusting the dose. For injectable esters the level peaks after a shot and drifts down before the next one, so the draw is timed to that cycle - a trough sample just before the next injection, or a mid-interval sample - rather than done at a random time. The formulation, not a universal rule, sets the timing.

Erythrocytosis - a rising red blood cell count - is the lab change most tied to testosterone therapy, which is why hematocrit and hemoglobin appear on essentially every monitoring list. The testosterone cypionate label states that these levels should be checked periodically in patients on long-term androgen therapy. The AndroGel label spells out a schedule: check hematocrit before treatment, re-evaluate it 3 to 6 months after starting, and then annually.

The threshold that matters here is 54%. The Endocrine Society guideline names a high hematocrit as the point to stop therapy and re-evaluate before considering a restart, and a 2024 Endocrine Connections review confirms the 54% figure as the general consensus across guideline bodies. The high hematocrit page covers that threshold and the levers around it in detail.

Prostate monitoring is age-weighted. The AUA guideline advises measuring PSA in men over 40 before starting therapy, and the Endocrine Society describes evaluating prostate cancer risk during the first year after initiation, with a urological referral triggered by a confirmed PSA rise or a prostate abnormality. Lipids are on the list too: the testosterone cypionate label notes that serum cholesterol may increase during androgen therapy, and the AndroGel label advises monitoring the lipid profile periodically.

Estradiol is the marker people expect to see on the list that the guidelines do not formally schedule. Testosterone aromatizes to estradiol, and estradiol matters for male bone, libido, and lipids, so many clinics track it alongside testosterone - but no guideline sets a required testing interval or a single optimal number for it. That is a debate rather than a settled figure, which the optimal estradiol page walks through. If your interest is in reading total versus free testosterone from a panel, the free testosterone calculator does that math from a lab report.

This is a reference to the monitoring cadence the guidelines and labels advise, not a prescription. Testosterone is a controlled substance, and the timing, the markers, and the thresholds for acting on a result are a decision for you and your prescriber. What is written here is what the cited documents say, so you can recognize the pattern - not a schedule to follow on your own.